SEC Form 4 · accession 0001193125-26-297818
Damora Therapeutics, Inc. · DMRA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Garrett Winslow
Officer — General Counsel
Period of report
Jul 3, 2026
Accepted (ET)
Jul 7, 2026 · 8:00 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001800315
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jul 3, 2026 | M | 680 | — | A | 2,534 | D | |
| Common Stock | Jul 6, 2026 | S | 245 | $29.98 | D | 2,289 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F3 | — | Jul 3, 2026 | M | 680 | D | — | — | Common Stock | 680 | 640 | D |
Explanation of responses
- F1Each restricted stock unit ("RSU") represents the right to receive, at settlement, one share of common stock of the Issuer. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date.
- F2Shares sold to cover tax obligations in connection with the vesting of the RSUs listed in Table II. This sale is mandated by the Issuer's election under its 2020 Equity Incentive Plan and does not represent a discretionary trade by the Reporting Person.
- F3This award was granted on January 3, 2024. One-third of the RSUs subject to the award vested on January 3, 2025 and one-sixth of the RSUs subject to the award award will vest ratably every six months thereafter, assuming continued employment through the applicable vesting date.